BioTuesdays

Tag - Charles Duncan

Cognition Logo
Markets

Cantor starts Cognition at OW; PT $12

Cantor Fitzgerald launched coverage of Cognition Therapeutics (NASDAQ:CGTX) with an “overweight” rating and 12-month price target of $12. The stock closed at $1.74 on Sept. 28. Cognition is a neuro-innovator leveraging...

September 29, 2022
MindMed Logo
Markets

Cantor starts MindMed at OW; PT $3

Cantor Fitzgerald launched coverage of MindMed (NASDAQ:MNMD) with an “overweight” rating and price target of $3. The stock closed at 58 cents on Aug. 9. MindMed is an early-stage neuro-innovator developing psychedelic...

August 10, 2022
biovie Logo
Markets

Cantor starts BioVie at OW; PT $7

Cantor Fitzgerald launched coverage of BioVie (NASDAQ:BIVI) with an “overweight” rating and $7 price target. The stock closed at $2.10 on July 21. BioVie is developing NE3107, an orally bioavailable anti-inflammatory...

July 22, 2022
vTv Therapeutics Logo
Markets

Cantor starts vTv at OW; PT $5

Cantor Fitzgerald launched coverage of vTv Therapeutics (NASDAQ:VTVT) with an “overweight” rating and 12-month price target of $5. The stock closed at 71 cents on Feb. 17. vTv is developing novel orally administered...

February 18, 2022
oramed
Markets

Cantor starts Oramed at OW; PT $20

Cantor Fitzgerald launched coverage of Oramed Pharmaceuticals (NASDAQ:ORMP) with an “overweight” rating and price target of $20. The stock closed at $10.63 on Feb. 17. Oramed is a developing novel drug formulations for...

February 18, 2022
Bionomics
Markets

Analysts start Bionomics at OW, OP

Analysts for Cantor Fitzgerald and William Blair launched coverage of Bionomics (NASDAQ:BNOX) with “overweight” and “outperform” ratings, respectively. Australia-based Bionomics is a clinical-stage biopharmaceutical...

January 10, 2022
Cardiol Therapeutics
Markets

Cantor starts Cardiol at OW; PT $8

Cantor Fitzgerald launched coverage of Cardiol Therapeutics (NASDAQ:CRDL) with an “overweight” rating and price target of $8. The stock closed at $1.87 on Dec. 16. Cardiol is a clinical-stage, platform-enabled...

December 17, 2021
Seelos Therapeutics Logo
Markets

Cantor starts Seelos Therapeutics at OW; PT $10

Cantor Fitzgerald launched coverage of Seelos Therapeutics (NASDAQ:SEEL) with an “overweight” rating and 12-to-18 month price target of $10. The stock closed at $3.08 on May 28. Analyst Charles Duncan, Ph.D., writes...

June 1, 2021
Clene-Nanomedicine
Markets

Cantor starts Clene at OW; PT $22

Cantor Fitzgerald launched coverage of Clene (NASDAQ:CLNN) with an “overweight” rating and 12-month price target of $22. The stock closed at $9 on April 30. Clene is a neuro-innovator that is developing drugs to enhance...

May 3, 2021
Markets

Cantor cuts Otonomy PT to $6 from $13

Cantor Fitzgerald slashed its price target for Otonomy (NASDAQ:OTIC) to $6 from $13 but maintained its “overweight” rating, after the company announced that the Phase 3 study of OTIVIDEX in Ménière’s disease did not...

February 22, 2021